Shares of Rite Aid Corporation RAD have surged more than 17.6 percent in the past three months, as the stock has recently made a push make new all-time highs. With the company set to release earnings on Thursday, is now the time for traders to be taking profits in the drug store, or is the sky the limit for Rite Aid’s stock?

In the past couple of weeks, several top Wall Street firms have weighed in on Rite Aid. Here’s a summary of what they believe is in store for investors.

UBS

UBS analysts believe that the foundation is in place for Rite Aid to exceed Wall Street earnings consensus “by a fairly wide amount.” UBS has a Buy rating on Rite Aid and a $10 target for the stock.

Credit Suisse

Credit Suisse analysts believe that Rite aid “provides one of the more compelling risk/reward profiles in our space.” The firm has an Outperform rating on Rite Aid and a $10 target for the stock.

Deutsche Bank

Deutsche Bank analysts see…

Read the rest of this article (and all my other articles) for free on Benzinga by clicking here

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!